ADAA offers an annual award to an early career investigator for the best original research paper on neurobiology, psychopharmacology, psychosocial treatments, or experimental psychopathology of anxiety disorders and depression. The award will be presented at the ADAA 2020 Annual Conference (March 19-22, San Antonio, TX). 

The #ADAA2020 Awards Application Portal is now open. 

Please note that the deadline to apply is October 1, 2019.

Award Components

  • Complimentary registration to the ADAA Annual Conference ($600 value)
  • Recognition at the Opening Session
  • $500 award
  • Rapid publication in Depression and Anxiety
  • Assignment of a mentor from the ADAA Scientific Council
  • Invitation to participate in the 2020 award selection committee and get involved in other activities of the organization
  • Featured profile on the ADAA website

Award Eligibility

  • The award is restricted to investigators who have completed their terminal degree and are currently at a rank of assistant professor or below.
  • Individuals who are working to complete their degree are not eligible.
  • Applicants must be the first or senior author on the submitted paper, which must be original research on anxiety disorders, depression, and comorbid related disorders, focusing on neurobiology, psychosocial treatments, or experimental psychopathology.
  • The paper cannot be submitted or under review anywhere else from submission until notification about the award (including ADAA's Depression and Anxiety Journal).
  • ADAA Board Members and the ADAA Scientific Council members are are not eligible.
  • Applicants must be members of ADAA, but we welcome new members, so interested nonmembers should feel free to join and then submit.

Klein Award Reviewers: Naomi Simon, MD, Msc and Charles B. Nemeroff, MD, PhD

Katie Burkhouse quote_0.png

Klein Rebecca Price_0.png

     Christopher Lowry Klein Blurb_1.png

   Klein Erin Dunn_0.png

Have a question about the Donald Klein award? Please email Kesha Patel.

About Donald F. Klein

This award is named for Donald F. Klein, MD, who revolutionized psychiatric thinking through his discovery in the early 1960s that imipramine, a recently developed psychotropic medication, was effective in blocking panic attacks. Dr. Klein’s early contribution to the development of the DSM in large part gave birth to the modern branch of medical science dealing with the classification of disease of anxiety disorders. His early findings also heralded in the era of childhood anxiety disorders as biochemical disorders when he discovered that imipramine blocked childhood separation anxiety disorders.

In later years, Dr. Klein developed a compelling evolutionary-based hypothesis accounting for the etiology of panic disorders, which he terms “the false suffocation alarm theory of panic disorders.” His work remains relevant and topical to the present. Dr. Klein was the recipient of the 2005 ADAA Lifetime Achievement Award.

The Donald F. Klein Early Career Investigator Award is supported by Depression and Anxiety, the official journal of ADAA, published by Wiley-Blackwell, the scientific, technical, medical, and scholarly business of John Wiley & Sons, Inc.